Ed Evans Foundation
Cancer Research Wales
Since 2007 we have raised £68,527 for Cancer Research Wales
Taken from CRW's Website
Cancer Research Wales funds a great variety of projects in Wales, some large and some small but all considered important in our battle against the killer disease.
Among the most prominent of these is the Wales Cancer Bank which started sample collection in February 2005, and in 2010 we consented our 4,000th patient.
This represents an incredible commitment on the part of our patients, to whom we owe so much.
Worldwide, enormous strides are being made in our understanding of cancer, with the identification of the genes that play a part, great or small, in the development of a cancer or in its behavior. How does the Wales Cancer Bank fit into this picture?
Much of the research conducted on our samples has, to date, been directed at identifying new targets in cancer tissues, which may help in new drug development in the future, or which may help to identify cancers that behave in a particular way.
However, there is another important aspect that we can contribute to, and that is target validation. If a potential gene, protein, or other target is discovered, usually from a setting such as a clinical trial, which, though incredibly important, may have been conducted in a very selected population of patients, a question that immediately arises is; “Does this target reflect the ‘real world’, outside of a clinical trial setting, and in everyday medical practice?”
By testing our Wales Cancer Banks samples for such a target, this question could be answered. This is an arena in which we could really excel, and I predict that it will become increasingly important in years to come.
On other fronts, the work that we do fund by Cancer Research Wales’ Programme grant has yielded a number of significant research publications, notably in high quality international journals such as Cancer Research.
On the cancer immunology front, our group is one of very few worldwide to be working on the complex and bizarre structures called exosomes.
Our group has also completed and published a study showing the changes in the immune system in patients with prostate cancer during radiotherapy, and has been working with the Wales Cancer Bank to extend this knowledge in order to understand how cancer treatments affect the immune system and also what opportunities this may give us to develop immune therapies alongside existing treatments for cancer.
Our metastasis research group has continued to research into prostate cancer and in particular to unravel the incredibly complex picture of the role of Hepatocyte Growth Factor in prostate cancer and in breast cancer. Pleasingly, a number of strands of information, from our group and from others, which appeared to be quite separate, are now starting to come together, particularly in understanding the biology underlying the spread of cancers to bone.
We hope that this might be the opening of a further new chapter in understanding how cancer behaves and how it might be controlled.
As ever, our profound thanks go to our patients and their families, who have freely donated their time, and their tissue and blood samples, to our partner NHS organisations, whose support is essential in what we are trying to do, and above all, to all those people who, through their support and contributions to Cancer Research Wales, have made it all possible.